N-(furan-2-ylmethyl)-3-imidazo[1,2-b]pyridazin-3-ylbenzamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: N-(furan-2-ylmethyl)-3-imidazo[1,2-b]pyridazin-3-ylbenzamide
• 化学式: C₁₈H₁₄N₄O₂
• 分子量: 318.3
• InChiKey: ZTSHLKVEOQXAHK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  72.4
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Nitrogen bicyclic compounds as inhibitors for Scyl1 and Grk5
  申请人：Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.

  公开号：EP2818471A1

  公开（公告）日：2014-12-31

  The present invention relates to compounds assumed to be capable of modulating the activity of the proteins ScyI1 and Grk5, thereby regulating the expression and/or release of insulin as well as to pharmaceutical compositions containing such compounds and the use thereof especially for the treatment of a metabolic disease such as diabetes, obesity and impaired adipogenesis.

  本发明涉及假设能够调节蛋白质ScyI1和Grk5活性的化合物，从而调节胰岛素的表达和/或释放，以及包含此类化合物的药物组合物及其用途，特别是用于治疗糖尿病、肥胖和脂肪生成受损等代谢性疾病。
• KINASES AS TARGETS FOR ANTI-DIABETIC THERAPY
  申请人：MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.

  公开号：US20150079108A1

  公开（公告）日：2015-03-19

  The present invention is related to compound capable of modulating the activity and/or expression of the protein kinase GRK5, thereby enhancing the expression and/or release of insulin. The invention is further related to methods of identifying said compounds for the treatment of diseases of the carbohydrate metabolism. The invention is further related to methods of treatment of diseases of the carbohydrate metabolism, particularly diabetes mellitus type 2.
• US9458463B2
  申请人：——

  公开号：US9458463B2

  公开（公告）日：2016-10-04